Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS‐441524 in patients with COVID‐19: A limited case series

• Principais autores: Pyoeng Gyun Choe (Autor), Sae Im Jeong (Autor), Chang Kyung Kang (Autor), Liju Yang (Autor), SeungHwan Lee (Autor), Joo‐Youn Cho (Autor), Seung Seok Han (Autor), Dong Ki Kim (Autor), Sang Min Lee (Autor), Wan Beom Park (Autor), Myoung‐don Oh (Autor), Nam Joong Kim (Autor)
• Formato: Livro
• Publicado em: Wiley, 2022-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Remdesivir, an antiviral agent for the treatment of coronavirus disease 2019 (COVID‐19), is metabolized intracellularly, with these metabolites eliminated predominantly in urine. Because of a lack of safety and pharmacokinetic (PK) data, remdesivir is not currently recommended for patients...